Path Ex Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
2ndary - Private
- Investors
-
14
Path Ex General Information
Description
Developer of an extracorporeal blood-cleansing device designed for the diagnosis and treatment of sepsis. The company's device selectively removes pathogens, including multidrug-resistant bacteria and endotoxin from circulating blood, enabling health professionals to eliminate intact bacteria from the blood rather than trying to kill the infection.
Contact Information
Website
www.pathex.coCorporate Office
- 2450 Holcombe Boulevard
- Suite J
- Houston, TX 77021
- United States
Corporate Office
- 2450 Holcombe Boulevard
- Suite J
- Houston, TX 77021
- United States
Path Ex Timeline
Path Ex Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 19. Secondary Transaction - Private | 01-May-2026 | Completed | Pre-Clinical Trials | |||
| 18. Seed Round | 25-Apr-2025 | Completed | Pre-Clinical Trials | |||
| 17. Grant | 23-Sep-2021 | Completed | Pre-Clinical Trials | |||
| 16. Seed Round | 30-Jun-2021 | Completed | Pre-Clinical Trials | |||
| 15. Grant | 05-Feb-2021 | Completed | Pre-Clinical Trials | |||
| 14. Accelerator/Incubator | 22-Oct-2020 | Completed | Pre-Clinical Trials | |||
| 13. Seed Round | 01-Feb-2020 | Completed | Startup | |||
| 12. Accelerator/Incubator | 07-Nov-2019 | Completed | Startup | |||
| 11. Accelerator/Incubator | 01-Jan-2019 | $875K | Completed | Startup | ||
| 10. Seed Round | 08-Jan-2019 | $700K | $875K | Completed | Startup |
Path Ex Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-3 | ||||||||
| Seed-1 | ||||||||
| Seed-2 | 318,807 | $0.000010 | $0.74 | $9.31 | $9.31 | 1x | $9.31 | 13.37% |
| Seed | 281,199 | $0.000010 | $0.37 | $4.65 | $4.65 | 1x | $4.65 | 11.8% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Path Ex Patents
Path Ex Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3870969-A1 | Method for the capture and isolation of disease material from flowing matter | Inactive | 24-Oct-2018 | ||
| EP-3870969-A4 | Method for the capture and isolation of disease material from flowing matter | Inactive | 24-Oct-2018 | ||
| US-20210220818-A1 | Method for the capture and isolation of disease material from flowing matter | Inactive | 24-Oct-2018 | ||
| WO-2020086761-A1 | Method for the capture and isolation of disease material from flowing matter | Inactive | 24-Oct-2018 | ||
| JP-2024028779-A | Device for capture and removal of disease material from fluids | Pending | 05-Jan-2018 | A61M1/3679 |
Path Ex Signals
Path Ex Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Fitz Gate Ventures | Venture Capital | Minority | ||
| IAG Capital Partners | Venture Capital | Minority | ||
| Oakwood Circle Ventures | Venture Capital | Minority | ||
| Symbiotic Ventures | Venture Capital | Minority | ||
| MedTech Innovator | Accelerator/Incubator |
Path Ex FAQs
-
When was Path Ex founded?
Path Ex was founded in 2017.
-
Where is Path Ex headquartered?
Path Ex is headquartered in Houston, TX.
-
What is the size of Path Ex?
Path Ex has 8 total employees.
-
What industry is Path Ex in?
Path Ex’s primary industry is Other Devices and Supplies.
-
Is Path Ex a private or public company?
Path Ex is a Private company.
-
What is Path Ex’s current revenue?
The current revenue for Path Ex is .
-
How much funding has Path Ex raised over time?
Path Ex has raised $12.5M.
-
Who are Path Ex’s investors?
Fitz Gate Ventures, IAG Capital Partners, Oakwood Circle Ventures, Symbiotic Ventures, and MedTech Innovator are 5 of 14 investors who have invested in Path Ex.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process